Trial Profile

A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nevirapine (Primary) ; Lamivudine/stavudine/nevirapine; Lamivudine/zidovudine/nevirapine
Indications HIV-1 infections
Focus Adverse reactions; Pharmacogenomic
Acronyms GENPART

Most Recent Events

01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
10 May 2011 As of August 2010, 366 patients had been enrolled in the substudy
10 May 2011 Interim results of the genetic substudy were presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com